

Anthera Pharmaceuticals Inc  
 Form 4  
 March 08, 2010

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Sofinnova Management VI, L.L.C.

2. Issuer Name and Ticker or Trading Symbol  
 Anthera Pharmaceuticals Inc  
 [ANTH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 03/04/2010

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 10% Owner  
 \_\_\_\_ Other (specify below)

140 GEARY STREET, 10TH FLOOR

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SAN FRANCISCO, CA 94108

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |   |                  |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |   |                  |
| Common Stock                    | 03/04/2010                           |  | C                              |   | 384,175   | A  | ① 384,175   | I | See footnote (2) |
| Common Stock                    | 03/04/2010                           |  | C                              |   | 828,323   | A  | ③ 1,212,498   | I | See footnote (2) |
| Common Stock                    | 03/04/2010                           |  | C                              |   | 864,855   | A  | ④ 2,077,353   | I | See footnote (2) |
| Common                          | 03/04/2010                           |  | C <sup>(8)</sup>               |   | 236,032   | A  | \$ 2,313,385  | I | See              |

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

|              |            |  |                  |         |   |         |           |   |                         |
|--------------|------------|--|------------------|---------|---|---------|-----------|---|-------------------------|
| Stock        |            |  |                  |         |   | 5.25    |           |   | footnote<br>(2)         |
| Common Stock | 03/04/2010 |  | C <sup>(8)</sup> | 350,056 | A | \$ 5.25 | 2,663,441 | I | See<br>footnote<br>(2)  |
| Common Stock | 03/04/2010 |  | C <sup>(8)</sup> | 155,127 | A | \$ 6.58 | 2,818,568 | I | See<br>footnote<br>(2)  |
| Common Stock | 03/04/2010 |  | A                | 744,496 | A | \$ 6.58 | 3,563,064 | I | See<br>footnote<br>(2)  |
| Common Stock | 03/04/2010 |  | A                | 420,166 | A | \$ 7    | 3,983,230 | I | See<br>footnote<br>(2)  |
| Common Stock | 03/04/2010 |  | A                | 83,246  | A | \$ 7    | 4,066,476 | I | See<br>footnote<br>(9)  |
| Common Stock | 03/04/2010 |  | A                | 5,727   | A | \$ 7    | 4,072,203 | I | See<br>footnote<br>(10) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |              |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title        |
| Series A-2 Convertible Preferred Stock     | (1)  | 03/04/2010                           |  | C                              | 384,175   | (1)  | (5)   | Common Stock |
| Series B-1 Convertible Preferred Stock     | (3)  | 03/04/2010                           |  | C                              | 828,323   | (3)  | (5)   | Common Stock |



## Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

(9) Shares are held by Sofinnova Venture Partners VI Gmbh KG ("SFV Gmbh IV"). SV VI LLC is the general partner of SFV Gmbh IV, and James I. Healy, a director of the issuer, Michael F. Powell, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SFV Gmbh IV. Such persons and entities disclaim beneficial ownership of shares held by SV VI except to the extent of any pecuniary interest therein.

(10) Shares are held by Sofinnova Venture Affiliates VI L.P. ("SVA"). SV VI LLC is the general partner of SVA, and James I. Healy, a director of the issuer, Michael F. Powell, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SVA. Such persons and entities disclaim beneficial ownership of shares held by SV VI except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.